TipRanks on MSN

Travere Therapeutics’ Study on Homocystinuria: A Closer Look at the ACAPPELLA Study

Travere Therapeutics, Inc. (($TVTX)) announced an update on their ongoing clinical study. Travere Therapeutics, Inc. is conducting a study titled ...
Seeking Alpha

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...
Seeking Alpha

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study ...
Nasdaq

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria

REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food ...
Gulf Times

WCM-Q in mission to discover drug candidates for homocystinuria

Denovo Sciences Inc, a pioneer in AI-driven drug discovery based on synthetic data, Weill Cornell Medicine-Qatar (WCM-Q), and Sidra Medicine are engaging in a collaboration to identify and develop ...